Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Accumulated Expenses (2020 - 2025)

Insight Molecular Diagnostics' Accumulated Expenses history spans 6 years, with the latest figure at $2.2 million for Q3 2025.

  • For Q3 2025, Accumulated Expenses rose 99.64% year-over-year to $2.2 million; the TTM value through Sep 2025 reached $2.2 million, up 99.64%, while the annual FY2024 figure was $1.1 million, 32.32% down from the prior year.
  • Accumulated Expenses for Q3 2025 was $2.2 million at Insight Molecular Diagnostics, up from $1.5 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $4.1 million in Q3 2022 and bottomed at $1.1 million in Q3 2023.
  • The 5-year median for Accumulated Expenses is $2.0 million (2022), against an average of $2.1 million.
  • The largest annual shift saw Accumulated Expenses tumbled 72.56% in 2023 before it soared 99.64% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $2.8 million in 2021, then dropped by 28.48% to $2.0 million in 2022, then decreased by 18.45% to $1.6 million in 2023, then crashed by 32.32% to $1.1 million in 2024, then soared by 99.64% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Accumulated Expenses are $2.2 million (Q3 2025), $1.5 million (Q2 2025), and $1.1 million (Q1 2025).